Adela to present data demonstrating detection of multiple cancer types at the American Association for Cancer Research Annual Meeting 2023

FOSTER CITY, Calif., March 15, 2023 /PRNewswire/ -- Adela, Inc. announced today that it will present data demonstrating the ability of its genome-wide methylome enrichment platform to detect multiple types of cancer at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. The cohort to be presented is comprised of cancer cases (individuals with newly diagnosed treatment-naïve cancer) and age- and gender-matched non-cancer controls.

‍

Adela's genome-wide methylome enrichment platform has the potential to detect early-stage disease with best-in-class performance because of the breadth of information captured through the whole methylome approach. The platform specifically isolates the highly informative (methylated) regions of the genome, enabling it to more efficiently capture broad genomic information and preserve it during sequencing compared to other platforms that use enzymatic or chemical treatment (bisulfite conversion). The platform’s potential advantage in detecting early-stage disease enables applications in both multi-cancer early detection and cancer management, including minimal residual disease detection and disease monitoring.

‍

Presentation Details

‍

Park, Ben MD, PhD et al.¹ Development of a Genome-Wide Methylome Enrichment Platform for Multi-Cancer Early Detection (MCED)

Abstract number: 1030

Session date and time: Sunday Apr 16, 2023 1:30 - 5:00 PM ET

Location: Section 42 Poster Board Number 7

About Adela

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test. The company’s genome-wide methylome enrichment platform captures information from small quantities of cell-free DNA and applies machine learning to detect and classify underlying disease. The platform specifically isolates the highly informative (methylated) regions of the genome through a high-affinity enrichment process, enabling it to more efficiently capture broad genomic information and preserve it during sequencing compared to other platforms that use enzymatic or chemical treatment (bisulfite conversion). The technology is initially being developed for use across the cancer continuum for detection and management, and in the future will be applied to other conditions beyond cancer. Adela’s investors are F-Prime Capital, OrbiMed, Deerfield Management, Decheng Capital, and RA Capital Management. Find more information at adelabio.com

Media Contact

PR@adelabio.com

‍

¹^{Vanderbilt-Ingram Cancer Center, Nashville, TN}

March 15, 2023

Adela to present data demonstrating detection of multiple cancer types at the American Association for Cancer Research Annual Meeting 2023

RECENT UPDATES

Adela to Present Biological Insights into its Tissue-Agnostic Assay for Molecular Residual Disease Detection at the AACR Special Conference in Cancer Research

Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024

Adela to Present Data Supporting Use of its Tissue-Agnostic MRD Assay for Recurrence Prediction and Monitoring in Patients with Head & Neck Cancer at the American Society of Clinical Oncology 2024 Meeting